
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HOPO 14-1
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase I
Sponsor : BARDA
Deal Size : $226.0 million
Deal Type : Funding
HOPO Awarded Up to $226 Million from BARDA for Development of its Oral Decorporation Agent
Details : The funds will be used to advance development of the drug candidate HOPO-101 as a possible treatment for lead poisoning.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : HOPO 14-1
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase I
Sponsor : BARDA
Deal Size : $226.0 million
Deal Type : Funding

Contact Us!